Crinetics Pharmaceuticals Inc
6197 Cornerstone Court E #111
10 articles with Crinetics Pharmaceuticals Inc
One year after Vivek Ramaswamy launched Urovant Sciences to develop urological therapies, the company is now seeking $150 million from an initial public offering.
Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals has secured $63.5 million in Series B financing.
Mr. Wilson joins Crinetics from Cidara Therapeutics, where he was Vice President of Finance and Accounting and Chief Accounting Officer.
CRN00808 is a nonpeptide somatostatin agonist designed to be taken orally to free patients from painful injected therapies and the scheduling of frequent clinic visits to receive them.
Crinetics Awarded Two SBIR Grants To Develop New Therapeutics For Congenital Hyperinsulinism And Cushing’s Disease
Crinetics Pharmaceuticals Awarded National Institutes of Health (NIH) Phase-II SBIR Grant to Develop Drugs for Pituitary Tumors
National Institutes of Health (NIH) Awarded Crinetics Pharmaceuticals Small Business Innovative Research Grant To Develop Gpcr Biosensors For Drug Discovery